Natascia Di Iorgi1, Tiziana Muratori2, Andrea Secco1, Flavia Napoli1, Nadia Fratangeli1, Francesca De Terlizzi3, Giovanna Giorgiani2, Franco Locatelli2, Mohamad Maghnie4. 1. Department of Pediatrics, IRCCS G. Gaslini, University of Genova, Largo Gerolamo Gaslini, 5, 16147, Genova, Italy. 2. Department of Pediatric Hematology/Oncology, IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy. 3. IGEA Biophysics Laboratory, Carpi, Italy. 4. Department of Pediatrics, IRCCS G. Gaslini, University of Genova, Largo Gerolamo Gaslini, 5, 16147, Genova, Italy. Electronic address: mohamadmaghnie@ospedale-gaslini.ge.it.
Abstract
PURPOSE: Bone marrow transplantation (BMT) recipients are at risk of bone mass impairment and skeletal morbidity. We investigated bone status with quantitative ultrasound (QUS) technique in children and adolescents with hematological diseases before and after BMT. METHODS: Phalangeal QUS measures for amplitude-dependent speed of sound (AD-SoS) and bone transmission time (BTT) were obtained in 144 hematological patients (81M, 63F; 11.6+/-5.2 years); forty two were evaluated before BMT and 102 after allogeneic or autologous BMT. Bone parameters were expressed as Z-scores based on age-sex-matched normal controls. RESULTS: Mean BTT Z-score was reduced in subjects after BMT compared to patients before BMT (M, -0.35+/-1.04 vs. 0.70+/-1.11, P<0.001; F, -0.60+/-1.23 vs. 0.23+/-1.17, P<0.05). Females and males with hormone deficiencies showed reduced BTT Z-scores when compared with subjects without hormone defects (M, -0.52+/-1.0 vs. 0.05+/-1.17, P<0.05; F, -0.50+/-1.27 vs. -0.19+/-1.26; P=0.06). AD-SoS and BTT Z-scores were reduced in 15 subjects with fractures and/or avascular osteonecrosis compared to patients without bone events (-1.52+/-1.7 vs. -0.41+/-1.32 and -0.85+/-1.19 vs. -0.10+/-1.18; both Ps<0.05). Bone event cumulative incidence was 4 times greater in subjects who suffered from chronic GVHD. CONCLUSIONS: Assessment of phalangeal QUS in young BMT survivors points towards impairment of bone status and endocrine dysfunction and chronic GVHD as risk factors of adverse bone events.
PURPOSE: Bone marrow transplantation (BMT) recipients are at risk of bone mass impairment and skeletal morbidity. We investigated bone status with quantitative ultrasound (QUS) technique in children and adolescents with hematological diseases before and after BMT. METHODS: Phalangeal QUS measures for amplitude-dependent speed of sound (AD-SoS) and bone transmission time (BTT) were obtained in 144 hematological patients (81M, 63F; 11.6+/-5.2 years); forty two were evaluated before BMT and 102 after allogeneic or autologous BMT. Bone parameters were expressed as Z-scores based on age-sex-matched normal controls. RESULTS: Mean BTT Z-score was reduced in subjects after BMT compared to patients before BMT (M, -0.35+/-1.04 vs. 0.70+/-1.11, P<0.001; F, -0.60+/-1.23 vs. 0.23+/-1.17, P<0.05). Females and males with hormone deficiencies showed reduced BTT Z-scores when compared with subjects without hormone defects (M, -0.52+/-1.0 vs. 0.05+/-1.17, P<0.05; F, -0.50+/-1.27 vs. -0.19+/-1.26; P=0.06). AD-SoS and BTT Z-scores were reduced in 15 subjects with fractures and/or avascular osteonecrosis compared to patients without bone events (-1.52+/-1.7 vs. -0.41+/-1.32 and -0.85+/-1.19 vs. -0.10+/-1.18; both Ps<0.05). Bone event cumulative incidence was 4 times greater in subjects who suffered from chronic GVHD. CONCLUSIONS: Assessment of phalangeal QUS in young BMT survivors points towards impairment of bone status and endocrine dysfunction and chronic GVHD as risk factors of adverse bone events.
Authors: A Mussa; F Porta; G Baldassarre; G Tuli; F de Terlizzi; P Matarazzo; S Einaudi; R Lala; A Corrias Journal: Osteoporos Int Date: 2011-09-23 Impact factor: 4.507
Authors: Kuan Chung Wang; Kuan Chieh Wang; Afsaneh Amirabadi; Edward Cheung; Elizabeth Uleryk; Rahim Moineddin; Andrea S Doria Journal: Pediatr Radiol Date: 2014-06-25
Authors: N Di Iorgi; E Calandra; A Secco; F Napoli; A Calcagno; M Ghezzi; C Frassinetti; F De Terlizzi; G Giorgiani; F Locatelli; M Maghnie Journal: J Endocrinol Invest Date: 2010-01-22 Impact factor: 4.256